We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current QNCX market cap is 30.32M. The company's latest EPS is USD -0.7262 and P/E is -2.69.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -12.96M | -5.58M | -6.16M | -9.92M | -11.22M |
| Net Income | -12.25M | -4.89M | -5.35M | -8.89M | -11.15M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -39.17M | -78.89M | -90.32M | -52.02M | -34.62M |
| Net Income | -36.98M | -76.85M | -89.95M | -51.66M | -31.39M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 93.32M | 88.84M | 85.39M | 167.9M | 159.29M |
| Total Liabilities | 3.12M | 1.95M | 2.25M | 82.82M | 85.12M |
| Total Equity | 90.2M | 86.88M | 83.13M | 85.08M | 74.18M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 124.37M | 189.47M | 133.23M | 103.91M | 167.9M |
| Total Liabilities | 8.89M | 17.2M | 14.64M | 3.32M | 82.82M |
| Total Equity | 115.48M | 172.26M | 118.59M | 100.59M | 85.08M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -3.57M | -7.4M | -12.21M | -18.29M | -8.35M |
| Investing | 5.54M | -14.78M | -11.15M | -5.76M | 8.91M |
| Financing | 50k | 76k | 86k | 143k | 190k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -33.28M | -50.82M | -62.93M | -44.04M | -18.29M |
| Investing | -17.75M | -52.43M | 58.95M | 18M | -5.76M |
| Financing | 77.37M | 118.88M | 6.81M | 707k | 143k |
| Market Cap | 30.32M |
| Price to Earnings Ratio | -2.69 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 4.06 |
| Price to Book Ratio | 0.99 |
| Dividend Yield | - |
| Shares Outstanding | 43.22M |
| Average Volume (1 week) | 110.1k |
| Average Volume (1 Month) | 121.66k |
| 52 Week Change | -52.92% |
| 52 Week High | 1.70 |
| 52 Week Low | 0.6331 |
| Spread (Intraday) | 0.11 (13.89%) |
| Company Name | Quince Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://quincetx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
